Showing recent highlights
What's New
PubMed · September 1, 2026
Researchers found that a structured self-management program — where people with chronic conditions like type 2 diabetes learn skills to manage their health day-to-day — led to lasting improvements in sleep, pain, fatigue, and mood, even six months after the program ended, across many different countries. For someone with type 2 diabetes, this matters because managing a long-term condition involves a lot more than just medication — things like energy levels, sleep, and emotional well-being all affect how well someone can stay on top of their health. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · September 1, 2026
A study found that women with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and stiffness — who practiced yoga for 8 weeks in a row reported noticeably less pain, better balance, less fatigue, and improved mood compared to women who did a mixed exercise program or no structured exercise at all. The yoga group's pain scores dropped about twice as much as those in the combined exercise group, and these benefits were still measurable 20 weeks after the program ended. Researchers think the breathing and relaxation techniques built into yoga may be a big part of why it worked so well.
What's New
PubMed · September 1, 2026
Researchers found that people with rheumatoid arthritis who have a higher body weight (measured by BMI, a ratio of weight to height) may respond less well to a group of medications called JAK inhibitors — which includes drugs like tofacitinib and baricitinib — compared to people with a lower body weight. This was discovered by pooling and re-analyzing data from 16 separate studies involving nearly 12,000 patients, making it one of the largest looks at this question so far. For someone living with rheumatoid arthritis and managing their weight, this could be an important piece of the puzzle when talking with their doctor about which treatment might work best for them. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that gently stimulating a nerve near the base of the spine — using thin needles similar to acupuncture — may help calm the nervous system in people with rheumatoid arthritis, a condition where the immune system attacks the joints causing pain and swelling. People who received the real stimulation showed signs of improved nervous system balance, which is interesting because an out-of-balance nervous system is thought to make inflammation worse. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · September 1, 2026
According to American College of Rheumatology guidelines, exercise is recommended for adults with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and stiffness — because it has been shown to improve physical function and reduce pain compared to no exercise. This new analysis looked at whether the evidence behind that recommendation is solid enough to be considered settled, and found that while the results are promising, more research is still needed before experts can say with full confidence that the picture is complete. For now, the guideline's support for exercise remains based on moderate-strength evidence, meaning it's a well-supported recommendation but not yet the final word.
What's New
PubMed · September 1, 2026
Researchers found that two types of hands-on physical therapy — one focusing on muscles and soft tissue, the other on gently moving the joints themselves — both helped people with rheumatoid arthritis who also had jaw joint problems (a condition called temporomandibular disorder, where the jaw joint causes pain or stiffness). After six weeks of twice-weekly sessions, people in both therapy groups could open and move their jaws more freely and reported lower anxiety levels, while people who received no treatment actually got a little worse over time. This matters because jaw problems are common in rheumatoid arthritis and are sometimes overlooked, so knowing that hands-on therapy may help could be encouraging for people dealing with both conditions. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with chronic pain conditions — including fibromyalgia, rheumatoid arthritis, and knee or hip osteoarthritis — reported improvements in pain, mental health, and physical functioning after taking capsules containing different combinations of cannabis compounds over 12 weeks. All three formulas tested showed benefits, though none stood out as clearly superior to the others. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with early rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who had higher levels of a natural protein called interleukin-10 in their blood were more likely to respond well to a medication called abatacept, and also showed less joint bone damage over time. This suggests that a simple blood marker might one day help doctors predict which patients are most likely to benefit from this particular treatment before they even start it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — use physical and occupational therapy at very different rates depending on where they live, with people in European countries generally receiving these services more often than those in North America. The review also found that physical therapy was used far more than occupational therapy, which helps people manage daily tasks affected by their condition. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 31, 2026
Researchers found that Japanese patients with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who took a medication called upadacitinib on its own did better over five years than those who took methotrexate, a commonly used treatment, on its own. People taking upadacitinib also had less joint damage building up over time, which matters because joint damage can affect movement and quality of life in the long run. The higher dose of upadacitinib did come with more side effects, so this is something people with rheumatoid arthritis might want to discuss with their doctor. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 31, 2026
Researchers found that filgotinib, a medication used to treat moderate to severe rheumatoid arthritis, appeared to be well-tolerated over up to 5 years in a group of Japanese patients — with no cases of dangerous blood clots and very few deaths reported during that time. The most notable side effects were serious infections and a viral condition called herpes zoster (a painful skin rash related to the chickenpox virus), though these occurred at relatively low rates. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 31, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints — who took a newer biologic treatment called ozoralizumab sometimes developed antibodies against the drug itself, which could weaken how well it worked. However, when ozoralizumab was taken alongside a common companion drug called methotrexate, those drug-fighting antibodies were less likely to form, and the treatment kept working better for longer. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · August 30, 2026
A type of cancer treatment called CAR T-cell therapy — which involves retraining a person's own immune cells to attack a specific target — showed striking results in six people with severe rheumatoid arthritis that hadn't responded to other treatments. Three of those people reached remission, meaning their symptoms stopped, without needing any medication at all. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 20, 2026
Researchers found that tailoring rheumatoid arthritis treatment to each patient — by choosing the first medication based on the patient's specific antibody type and checking in sooner if symptoms weren't improving — may help reduce the need for stronger, more intensive medications down the line compared to the standard one-size-fits-all approach. For people living with rheumatoid arthritis, this matters because it suggests that a more personalized strategy early on could lead to better outcomes with potentially fewer medication escalations. This is early research and hasn't yet changed treatment guidelines.
Watch Out For
FDA MedWatch · August 11, 2026
Be aware that a specific batch of Tyenne (tocilizumab-aazg) injection vials has been recalled nationwide because tiny glass particles were found inside them. If patients or caregivers have this medication at home or in a care setting, they should check whether their vials are part of the recalled lot and contact their doctor or pharmacist right away before using it.
Ask your doctor: Ask the doctor whether the patient's Tyenne injection for rheumatoid arthritis might be affected by the recent recall due to glass particles, and what the patient should do about any doses the patient may have at home.
What's New
ScienceDaily · August 6, 2026
A press release highlights that tiny particles in the air — like smoke, soot, and dust — may make rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling) worse over time, and could trigger painful flares. For people living with this condition, air quality may turn out to be an important but often overlooked part of managing their health. Researchers suggest that paying attention to pollution levels, especially over long periods, could matter for how well the disease is kept under control.
Guidelines
PubMed · August 4, 2026
Researchers reviewed 131 studies on rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — that is hard to treat. They found that most medications studied worked better than a placebo (a dummy treatment) in people whose arthritis hadn't responded to multiple previous treatments, and that one class of medications called JAK inhibitors (pills that calm the immune system) continued to work even after several other treatments had failed — though they were also linked to a higher chance of infections and certain cancers. People with hard-to-treat rheumatoid arthritis and their doctors may want to have an open conversation about these trade-offs when considering next steps.
What's New
PubMed · August 1, 2026
Researchers found that a treatment called therapeutic apheresis — a process that filters the blood to remove substances thought to drive inflammation — showed no clear overall benefit for people with rheumatoid arthritis, a condition where the immune system attacks the joints. However, when researchers looked more closely at specific types of apheresis, some differences emerged that could be worth exploring further. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that certain medications — including methotrexate, tocilizumab, and rituximab — were linked to lower rates of death in people with rheumatoid arthritis who also developed a serious lung condition called interstitial lung disease (where scar tissue builds up in the lungs, making it harder to breathe). The study also found that a class of medications called JAK inhibitors (such as Xeljanz or Rinvoq) had the highest rate of people staying on treatment, which suggests patients may tolerate them well. For someone with rheumatoid arthritis, this matters because lung complications are one of the more serious risks of the disease, and understanding which treatments might help protect the lungs is an important area of ongoing research. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a 12-week program of high-intensity interval exercise did not meaningfully reduce deep belly fat (the kind stored around the organs, which raises the risk of heart disease) in people with rheumatoid arthritis — and this was true whether patients were taking a TNF-blocking medication or an IL-6-blocking medication, two common types of biologic treatments for the condition. Scientists had wondered whether IL-6-blocking drugs might interfere with exercise's ability to burn belly fat, since IL-6 is a natural signal the body uses during exercise to release stored fat, but this study found no meaningful difference between the two medication groups. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that for people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who had reached a stable, symptom-free period, completely stopping their biologic medication (a type of drug that calms the immune system) was more than twice as likely to cause their symptoms to flare up again compared to simply lowering the dose. The good news is that most people who did flare were able to get their symptoms back under control by restarting or adjusting their medication. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should try lowering the dose of their biologic medicine instead of stopping it completely if their rheumatoid arthritis stays under control.
What's New
PubMed · August 1, 2026
Researchers found that people who are natural 'night owls' — meaning they feel most alert in the evening and tend to go to bed late — were about 67% more likely to report living with chronic pain compared to people who naturally wake early or keep more typical schedules. This pattern showed up across many types of pain, including muscle and joint pain and headache disorders, after combining results from 43 separate studies. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who come from ethnic minority backgrounds or don't speak the local language as their first language often face real hurdles when trying to learn about their condition and its treatments, including a lack of awareness about rheumatoid arthritis, distrust of healthcare professionals, and worries about whether treatments are safe or worth taking. These barriers can make it harder for people to stay on top of their care and feel confident in the decisions they're making alongside their doctor. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that when doctors adjust the dose of certolizumab pegol — a medication used to treat rheumatoid arthritis, a condition where the immune system attacks the joints — the amount of the drug in a patient's blood changes in a very predictable way, roughly doubling when the dose is doubled and dropping by about half when the dose is lowered. This matters because knowing how drug levels shift with dose changes could help doctors fine-tune treatment more precisely for each person, making sure they're getting enough medication to keep their arthritis under control without unnecessarily high amounts. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that two different surgical options for repairing a damaged thumb joint — a dissolvable implant called RegJoint and a traditional technique that uses a patient's own tendon to cushion the joint — produced similar results for people with rheumatoid arthritis when checked again about 15 years later. Both groups had comparable pain levels and hand function over the long run, though grip strength declined in both groups over time, and people with the implant reported more pain at the final check-in. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 25, 2026
Researchers found that adding a traditional Chinese medicine technique called separated moxibustion — where heat from burning herbs is applied over specific points on the skin — to standard drug treatment helped people with rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling) experience less joint pain, less morning stiffness, and lower levels of anxiety and depression compared to those who only received standard drugs. The researchers also noticed changes in the gut microbiota, meaning the community of bacteria living in the digestive system, suggesting the treatment may work partly by influencing those bacteria and reducing inflammation. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 13, 2026
Researchers found that when people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — don't get enough relief from their first treatment, there are many other medications available, but it hasn't been clear which ones work best or are safest compared to each other. This large review looked at studies comparing dozens of different options to help sort out which treatments tend to work better after the first one falls short. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 10, 2026
Researchers found that for people with rheumatoid arthritis — a condition where the immune system attacks the joints — taking certain newer medications alongside older standard treatments may raise the risk of serious infections more than taking either type alone. Specifically, combining older standard drugs with four particular medications (adalimumab, infliximab, tofacitinib, or upadacitinib) was linked to a noticeably higher chance of serious infections, while some other drug combinations did not show the same pattern. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 3, 2026
A study found that older adults (over 65) with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — responded just as well to a structured treatment approach as younger patients, and were actually more likely to reach a state where the disease was no longer actively causing symptoms. Older patients also needed fewer of the stronger medications used when standard treatments aren't enough, suggesting this approach works well even for people with other health conditions alongside their arthritis. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a traditional herbal formula called Kunduan Yimu Decoction may help reduce joint inflammation and other symptoms in people with rheumatoid arthritis — a condition where the immune system mistakenly attacks the joints — possibly by influencing a tiny molecule in the body that helps cells clean up damage and keep inflammation in check. The herbal formula was compared to methotrexate, a commonly used medication for rheumatoid arthritis, in a small study of 66 patients over 12 weeks. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.